Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses (Nature Medicine, (2021), 27, 2, (279-288), 10.1038/s41591-020-01179-4)

the Oxford COVID Vaccine Trial Group

Research output: Contribution to journalComment/debate

2 Citations (Scopus)

Abstract

In the version of this article initially published, the numbers of cells in the third sentence of the second paragraph of the Methods subsection ‘Antibody-dependent neutrophil phagocytosis’ (500,000) and in the fifth sentence of the first paragraph of the Methods subsection ‘Antibody-dependent monocyte phagocytosis’ (250,000) were incorrect. The correct numbers are 50,000 and 25,000 (respectively). The errors have been corrected in the HTML and PDF versions of the article. *A full list of authors and their affiliations appears at the end of the paper.

Original languageEnglish
Pages (from-to)1113
Number of pages1
JournalNature Medicine
Volume27
Issue number6
DOIs
Publication statusPublished - Jun 2021

Bibliographical note

Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Nature America, Inc.

Fingerprint

Dive into the research topics of 'Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses (Nature Medicine, (2021), 27, 2, (279-288), 10.1038/s41591-020-01179-4)'. Together they form a unique fingerprint.

Cite this